ArticleScientific reports2026
Cell-free adipose tissue-derived stem cell extracts mediate immunosuppression of lymphocyte via cell cycle arrest.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free mesenchymal stem cell products have shown promise in reducing inflammation, alleviating tissue degeneration, and regulating immune responses. A recent study has reported that adipose tissue-derived stem cell (ADSC) extract possesses immunomodulatory capacity. However, its comparative efficacy against other cell-free products is not well documented. Nevertheless, the underlying mechanism of ADSC extract is under intense investigation. We determined the immunosuppressive efficiency of ADSC extract and ADSC-concentrated conditioned medium (CCM) on T cell proliferation, T regulatory cell expansion, and T cell cycle progression. In addition, the comparative cytokine profiles of ADSC extract and ADSC-CCM were investigated by cytokine array analysis. The ADSC extracts were superior in inhibiting T cell proliferation, promoting T regulatory cell expansion, and inducing activated T cell arrest at G0/G1 phase compared with ADSC-CCM. The inhibitory effect of ADSC extract on T cell proliferation was partly associated with control of cell cycle progression but not apoptosis induction. A halt in cell cycle progression of activated T lymphocyte after ADSC extract exposure was mediated via p21 and p27 activation. The cytokine profiling demonstrated that there were distinct patterns of immunoregulatory components in ADSC extract and ADSC-CCM, likely associated with their differing in immunoregulatory actions. The marked expression of TGF-β1 and IL-10 in the composition of ADSC extract implied their key roles in mediating immunosuppressive actions. IL-10 and TGF-β1 neutralization partly abrogated immunosuppressive capacities of ADSC extract. Together, ADSC extract may serve as an alternative source of immunomodulatory mediators with potential for development as cell-free products for therapeutic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.